Related references
Note: Only part of the references are listed.Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic HBV Infection: Systematic Review and Meta-analysis
Ryan T. Anderson et al.
Clinical Gastroenterology and Hepatology (2020)
The efficacy of hepatitis B treatments in achieving HBsAg seroclearance: A systematic review and meta-analysis
Mariana Alves Fonseca et al.
JOURNAL OF VIRAL HEPATITIS (2020)
Challenges, Considerations, and Principles to Guide Trials of Combination Therapies for Chronic Hepatitis B Virus
Ryan Taylor Anderson et al.
GASTROENTEROLOGY (2019)
Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B
Kin Seng Liem et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance
K. Qiu et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Treatment of hepatitis B: Is there still a role for interferon?
Mauro Vigano et al.
LIVER INTERNATIONAL (2018)
Hepatitis B cure: From discovery to regulatory approval
Anna S. Lok et al.
JOURNAL OF HEPATOLOGY (2017)
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
JOURNAL OF HEPATOLOGY (2017)
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial
Marc Bourliere et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection
M. Vigano et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability
Gi-Ae Kim et al.
GUT (2014)
Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)
Qin Ning et al.
JOURNAL OF HEPATOLOGY (2014)
HBsAg quantification: useful for monitoring natural history and treatment outcome
Michelle Martinot-Peignoux et al.
LIVER INTERNATIONAL (2014)
TELBIVUDINE (LDT) PLUS PEG-INTERFERON (PEGIFN) IN HBEAG-POSITIVE CHRONIC HEPATITIS B - VERY POTENT ANTIVIRAL EFFICACY BUT RISK OF PERIPHERAL NEUROPATHY (PN)
P. Marcellin et al.
JOURNAL OF HEPATOLOGY (2010)
Early HBeAg Loss During Peginterferon α-2b Therapy Predicts HBsAg Loss: Results of a Long-Term Follow-Up Study in Chronic Hepatitis B Patients
Erik H. C. J. Buster et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Share Paper
